Acorda Therapeutics

Acorda announces positive phase III CVT-301 results for Parkinson’s

Thursday, February 9, 2017

Acorda Therapeutics has announced phase III clinical data of CVT-301, showing a statistically significant improvement in motor function in people with Parkinson’s disease experiencing OFF periods. CVT-301 is an investigational, inhalable formulation of levodopa (L-dopa). It is being studied as a treatment for OFF periods in people with Parkinson’s disease taking an oral carbidopa/levodopa regimen. OFF periods refer to the re-emergence of Parkinson’s symptoms.

[Read More]

Acorda to discontinues PLUMIAZ for epilepsy

Tuesday, May 24, 2016

Acorda Therapeutics will discontinue development of PLUMIAZ (diazepam) Nasal Spray, an investigational therapy being studied for the treatment of seizure clusters in people with epilepsy. Data from the ongoing clinical trials do not demonstrate its bioequivalence to Diastat rectal gel, needed to re-file the New Drug Application (NDA) under section 505(b)(2). Specifically, the data demonstrated unexpectedly lower nasal mucosa absorption of diazepam in persons with epilepsy compared to studies in healthy volunteers.

[Read More]

Acorda Therapeutics to acquire Civitas Therapeutics

Thursday, September 25, 2014

Acorda Therapeutics, a biotechnology company based in Ardsley, N.Y., has entered into an agreement to acquire Civitas Therapeutics, a Chelsea, Mass.-based, privately held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a phase III treatment candidate for OFF episodes of Parkinson’s disease (PD). The acquisition also includes rights to Civitas’ proprietary ARCUS pulmonary delivery technology and manufacturing facility with commercial-scale capabilities.

[Read More]

Acorda Therapeutics acquires neuropathic pain assets

Thursday, July 11, 2013

Acorda Therapeutics, a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions, has acquired two neuropathic pain management assets from NeurogesX. Qutenza is approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia. The company also acquired NP-1998 (previously NGX-1998), a phase III ready, prescription strength capsaicin topical solution.

[Read More]

High school junior Natalie Ng wins International BioGENEius Challenge

Friday, April 26, 2013

Natalie Ng, a junior at Monta Vista High School in Cupertino, Calif., won the International BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. Ng’s research in breast cancer and biomarkers helped her stand out from the 13 other finalists from across the U.S., Canada and Australia competing for the Challenge’s top prize, a $7,500 cash award.

[Read More]